Oncotelic Therapeutics OTLC
OTC OTLC
$0.02 +0.00 (+0.00%)
At close: Oct 15, 2026 · 4:00 PM EDT

Oncotelic Therapeutics (OTLC) Non Operating Investment Income (2026)

Updated

Oncotelic Therapeutics (OTLC) reported Non Operating Investment Income of $300,000 for Q2 2026.

Analysis

Oncotelic Therapeutics (OTLC) Non Operating Investment Income (2026) Analysis & Trends

For FY2025, Oncotelic Therapeutics posted Non Operating Investment Income of $365.35 million.

  • By year, Non Operating Investment Income came in at $12,706 in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Op. Investment Inc. (Qtr)
1 Eli Lilly 1,109.83 Bn 1,078.42 Bn 19.71 Bn -
2 Johnson & Johnson 610.61 Bn 529.14 Bn 17.26 Bn -
3 AbbVie 500.66 Bn 473.77 Bn 12.70 Bn -
4 Merck 354.64 Bn 309.02 Bn 12.21 Bn -
5 Novartis Ag 291.14 Bn 255.13 Bn 11.24 Bn -
6 Astrazeneca 254.18 Bn 227.87 Bn 12.86 Bn -
7 Amgen 229.46 Bn 184.86 Bn 7.24 Bn -
8 Gilead Sciences 190.33 Bn 164.53 Bn 6.22 Bn -
9 Pfizer 167.92 Bn 114.57 Bn 10.94 Bn -
10 Oncotelic Therapeutics 8.28 Mn 7.42 Mn - 300,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 300,000.00
API Access

Oncotelic Therapeutics Non Operating Investment Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=OTLC&period=max&api_key=YOUR_API_KEY